In human PBMC assays, TRAM-34 inhibited thymidine incorporation more potently after lymphocyte preactivation than in resting cells, with substantial donor and stimulus dependence. Inhibition of resting-cell activation required 5–10 µM, which the authors considered potentially nonspecific. [1]
Activity is model-dependent: TRAM-34 at 10 µM did not reduce ATP- or silica-induced IL-1β release from primed primary mouse macrophages in a potassium-channel inhibitor screen. [3]
Functional inhibition of cloned and native IKCa1 currents
Cell-based study · COS-7 cells expressing human IKCa1 and activated human T lymphocytes [1]
Whole-cell recordings established nanomolar functional channel block. The tested channel panel supports relative ion-channel selectivity, not absence of other molecular targets.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response; Figure 3A illustrates 25 and 50 nM
- Exposure duration
- Block reached equilibrium in 3–6 min (triarylmethanes)
- Method
- External application during whole-cell patch clamp
- Reported limits
- Vehicle and meaning of the reported Kd ± terms are not specified for this endpoint in the retrieved main text.
Methods and source locations
Compound reported in the paper: TRAM-34; Compound label in the paper: 6b
Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.
Figure 3A-D; Table 1; Electrophysiology; Results: TRAM-34 Is a Highly Selective Inhibitor
Cloned human IKCa1 current inhibition: Hill fit to slope-conductance reduction at −80 mV; 1 µM pipette free Ca2+; Hill coefficient 1.2; 15 cells — Figure 3A-B and caption; Results channel-block paragraph
Native IKCa current inhibition in activated human T lymphocytes: Whole-cell patch clamp; residual Kv1.3 current blocked by ShK-Dap22 — Table 1, lymphocyte IK row; Figure 3D; Electrophysiology
Activation-state dependence of lymphocyte mitogenesis inhibition
Cell-based study · Human peripheral blood mononuclear cells from different donors; resting versus 48-h preactivated cells [1]
TRAM-34 suppressed mitogen-restimulated thymidine incorporation more potently in preactivated cells than in resting cells. Responses varied by donor and stimulus.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response, not a fixed treatment dose
- Exposure duration
- 60-min drug preincubation; 48-h mitogen stimulation/restimulation; thymidine during final 6 h
- Method
- Anti-CD3 antibody (5 ng/mL) or PMA (10 nM) plus ionomycin (175 nM) stimulation; corresponding preactivation for 48 h
- Co-treatment
- Mitogens are assay stimuli; cyclosporin A combination in Figure 4C is not adopted.
- Reported limits
- Drug vehicle and statistical meaning of EC50 ± terms not specified in retrieved assay text; donor subgroup sizes for fitted EC50 means are not given.
Methods and source locations
Compound reported in the paper: TRAM-34; Compound label in the paper: 6b
Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.
Figure 4A-B and caption; [3H]Thymidine Incorporation Assay; Results: TRAM-34 Suppresses Human T Lymphocyte Activation
Inhibition of thymidine incorporation after anti-CD3 restimulation of preactivated cells: [3H]Thymidine incorporation; Figure 4 includes preactivated cells from six donors and resting cells from three donors — Results lymphocyte activation paragraph; Figure 4A and caption
Inhibition after PMA plus ionomycin restimulation of preactivated cells: [3H]Thymidine incorporation in mixed T/B lymphocyte-containing PBMC population — Results lymphocyte activation paragraph; Figure 4B and caption
Activation of resting human lymphocytes: Little effect at nanomolar concentrations; authors suggest inhibition at higher concentrations may be nonspecific — Results lymphocyte activation paragraph; Figure 4A-B, open symbols
Rat and human CYP isoform inhibition panel
Biochemical assay · Recombinant rat CYP2C6, CYP2C11, CYP1A2 and CYP2B1; human CYP2C19, CYP19A1, CYP1A2 and CYP2B6 [2]
TRAM-34 inhibited several CYP isoforms at micromolar concentrations, while rat/human CYP1A2 and human CYP19A1 showed little or no inhibition up to 80 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response up to 80 µM
- Exposure duration
- Table 1: preincubation 10 or 15 min; reaction 17 or 30 min, depending on isoform
- Method
- Fluorescent product assays at 37°C; substrate concentrations near known Km; no-inhibitor control
- Vehicle
- 1% acetonitrile in fluorescence assays
- Reported limits
- No in vivo drug-interaction magnitude follows from this recombinant-enzyme panel.
Methods and source locations
Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34
Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.
Materials and Methods; Table 1; Results and Figures 1-2 with captions
Rat CYP isoform inhibition: EFC for CYP2C6/2B1; DBF for CYP2C11. TRAM-34 points: mean ± SEM of 3 experiments in triplicate; clotrimazole comparator — Table 1; Figure 1A,B,D and caption; Results rat CYP activity
Human CYP isoform inhibition: DBF for CYP2C19; EFC for CYP2B6. TRAM-34 points: mean ± SEM of 3 experiments in triplicate; clotrimazole positive control — Table 1; Figure 2A,D and caption; Results human CYP activity
Rat/human CYP1A2 and human CYP19A1 activity: Positive comparator inhibition demonstrated for human CYP1A2 (fluvoxamine) and CYP19A1 (ketoconazole); rat CYP1A2 clotrimazole response was partial; TRAM-34 did not significantly alter product fluorescence at 30 or 100 µM — Figures 1C and 2B-C; Methods fluorescence interference check
Substrate-dependent modulation of human CYP3A4
Biochemical assay · Recombinant human CYP3A4 assayed with DBF, BFC or lovastatin [2]
TRAM-34 inhibited CYP3A4 with DBF and lovastatin but stimulated BFC turnover. A blanket claim that TRAM-34 lacks CYP activity is therefore unsupported.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response
- Exposure duration
- DBF: 10-min preincubation, 20-min reaction; BFC: 15-min preincubation, 5-min reaction; lovastatin: 20-min reaction
- Method
- Fluorescent DBF/BFC turnover or LC-MS/MS quantification of lovastatin metabolites
- Vehicle
- Fluorescence assays contained 1% acetonitrile
- Reported limits
- Do not transfer fluorescence-assay solvent conditions to the separate LC-MS/MS assay.
Methods and source locations
Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34
Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.
Table 1; Figures 3-4 and captions; CYP3A4 Assay with LVS as Substrate; Results CYP3A4 activity
CYP3A4-mediated DBF turnover: DBF 1 µM; mean ± SEM of 3 experiments in triplicate; ketoconazole positive control — Table 1; Figure 3A and caption
CYP3A4-mediated BFC turnover: BFC 50 µM; mean ± SEM of 3 experiments in triplicate; ketoconazole inhibited turnover — Table 1; Figure 3B and caption; Results CYP3A4 activity
Formation of two lovastatin metabolites by CYP3A4: Lovastatin 10 µM; LC-MS/MS; mean ± SEM of 3 experiments in duplicate; ketoconazole 10 µM inhibited both by >85% — Figure 4 printed curve labels and caption; Table 1; CYP3A4 assay methods
TRAM-34 negative comparator in macrophage IL-1β release
Cell-based study · Primary mouse bone marrow-derived macrophages, LPS-primed and challenged with ATP or silica [3]
TRAM-34 did not reduce IL-1β release in this comparator screen, whereas MCC950 and several broader potassium-channel inhibitors reduced release.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM TRAM-34
- Exposure duration
- 15-min pretreatment; ATP challenge 1 h or silica challenge 4 h
- Method
- IL-1β ELISA of supernatants after ATP (5 mM) or silica (300 µg/mL) challenge
- Vehicle
- 1% (vol/vol) DMSO
- Reported limits
- No direct KCa3.1 target-engagement measurement accompanies the negative TRAM-34 comparator; no universal absence of activity is inferred.
Methods and source locations
Compound reported in the paper: TRAM-34; Compound label in the paper: TRAM-34
Evidence applies to the named experimental material and model; no validation of SKU A12783 or a current Adooq lot.
Methods 2.1, 2.3, 2.12; Results 3.2; Figure 1ai-ii and caption
IL-1β release after ATP or silica challenge: ATP n=4; silica n=5; mean ± SEM; one-way ANOVA with Dunnett post hoc analysis. Vehicle and MCC950 comparator groups in Figure 1ai-ii — Figure 1ai-ii and caption; Results 3.2